Neurology Diagnostics


Memory Clinic

Alzheimer's Disease & Memory Care

Compassionate Care, Advanced Diagnostics & Innovative Treatment Opportunities


At Neurology Diagnostics and the Memory Clinic, we understand that experiencing memory changes or receiving an Alzheimer's disease diagnosis can bring uncertainty, questions, and concerns for both patients and their families. Led by Dr. Joel Vandersluis, a board-certified neurologist with over 30 years of experience, our practice is dedicated to providing comprehensive, compassionate neurological care for individuals living with Alzheimer's disease, memory loss, and other forms of dementia throughout Dayton, Ohio, and the surrounding communities.



Our goal is to help patients and their loved ones better understand their diagnosis, explore available treatment options, and feel supported throughout every stage of their care. By combining clinical expertise, advanced diagnostic technologies, FDA-approved treatments, and access to clinical research, we strive to provide patients with the knowledge and resources needed to make informed decisions about their neurological health.

Understanding Alzheimer's Disease: Diagnosis & Early Detection


Not all memory loss is caused by Alzheimer's disease, and identifying the underlying cause is an important first step toward appropriate care. Alzheimer's disease involves changes in the brain that can begin years before noticeable symptoms develop. Today, advances in diagnostic medicine allow physicians to evaluate memory concerns more thoroughly and, in appropriate patients, identify biological markers associated with Alzheimer's disease.



At Neurology Diagnostics, our diagnostic approach may incorporate several types of evaluations and specialized testing, including:

Comprehensive Neurological & Cognitive Evaluations: 

Detailed assessments of memory, thinking, language, daily functioning, and neurological health to identify patterns of cognitive change and evaluate for Alzheimer's disease or other forms of dementia.

Blood-Based Alzheimer's Biomarker Testing: 

Advances in blood testing allow physicians to evaluate biomarkers such as phosphorylated tau (p-tau) and indicators of amyloid-beta pathology, proteins associated with Alzheimer's disease. These tests can provide valuable information about the likelihood of Alzheimer's-related changes in the brain and help determine whether additional testing is appropriate.

Amyloid PET Imaging: 

Specialized brain imaging that allows physicians to identify amyloid plaque accumulation, one of the hallmark biological features of Alzheimer's disease. PET imaging can help clarify a diagnosis and determine eligibility for certain Alzheimer's treatments.

MRI & Other Brain Imaging:

Imaging studies that help evaluate brain structure, identify patterns of change, and rule out other potential causes of cognitive symptoms, including strokes, tumors, or other neurological abnormalities.

Evaluation for Other Causes of Memory Loss:

Laboratory testing, medication reviews, and additional clinical assessments to investigate potentially treatable conditions, such as thyroid disorders, vitamin deficiencies, sleep-related conditions, and other factors that may affect memory and cognitive function.

By combining these diagnostic approaches, Dr. Vandersluis works to establish a clearer understanding of each patient's condition, helping patients and families move forward with greater confidence and an individualized plan of care.

Alzheimer's Disease Treatment: More Options Than Ever Before


Although there is currently no cure for Alzheimer's disease, significant advancements in neurological medicine have expanded the treatment options available to patients. Some medications help manage symptoms and support everyday functioning, while newer therapies target biological changes associated with the progression of Alzheimer's disease.

Medications That Help Manage Symptoms


These FDA-approved treatments work by supporting communication between nerve cells in the brain. While they do not reverse Alzheimer's disease, they may help patients maintain memory, thinking, and daily functioning for a period of time.:

Donepezil (Aricept):

Helps increase the availability of acetylcholine, a brain chemical important for memory and learning. It is commonly prescribed for mild, moderate, and severe Alzheimer's disease.

Rivastigmine (Exelon):

Works similarly to donepezil by supporting communication between nerve cells. It is available in oral and transdermal patch formulations, providing additional options for patients who may have difficulty tolerating certain medications.

Galantamine (Razadyne): 

Another medication that helps support acetylcholine activity in the brain and may improve or stabilize certain cognitive symptoms in individuals with mild to moderate Alzheimer's disease.

Memantine (Namenda): 

Works differently from the medications above by regulating the activity of glutamate, a brain chemical involved in learning and memory. It is generally used for moderate to severe Alzheimer's disease and may be prescribed alone or alongside other Alzheimer's medications.

Newer Treatments That Target Alzheimer's Disease Progression


In recent years, the FDA has approved a new generation of Alzheimer's therapies designed to address one of the underlying biological features of the disease: amyloid plaque accumulation in the brain.

Leqembi (lecanemab): 

An anti-amyloid therapy that targets and helps remove amyloid-beta from the brain. Clinical studies have demonstrated that it can modestly slow cognitive and functional decline in eligible patients with early Alzheimer's disease.

Kisunla (donanemab): 

Another anti-amyloid treatment designed to reduce amyloid plaque accumulation in the brain. Like Leqembi, Kisunla has demonstrated an ability to slow disease progression in appropriately selected patients with early Alzheimer's disease.

These treatments represent meaningful advancements in Alzheimer's care, but they are not appropriate for every patient. Eligibility generally requires an early symptomatic stage of Alzheimer's disease, confirmation of amyloid pathology, and careful evaluation of medical history and potential risks. Anti-amyloid treatments also require ongoing monitoring, including MRI imaging, because of potentially serious side effects such as brain swelling or bleeding.


At Neurology Diagnostics, we believe patients and families should have the opportunity to understand both established and emerging treatment approaches, including their potential benefits, limitations, and safety considerations.

Expanding Alzheimer's Care Through Clinical Research


Dr. Vandersluis's approach to Alzheimer's care extends beyond diagnosing and managing symptoms. He combines personalized neurological care, advanced diagnostic tools, and access to innovative treatment opportunities to help patients explore the options available throughout their Alzheimer's journey.


Through our dedicated research division, NDx Clinical Research, Dr. Vandersluis has served as a Principal Investigator for clinical trials investigating new approaches to Alzheimer's disease treatment and prevention. These studies explore opportunities to improve symptom management, slow disease progression, and potentially intervene earlier in the disease process, sometimes before significant memory symptoms appear.


For some patients, participating in clinical research may provide an opportunity to explore investigational therapies alongside their established neurological care. Other studies may evaluate FDA-approved medications or follow patients receiving routine treatment to help researchers better understand Alzheimer's disease over time.

Our commitment is to ensure that patients and families never feel they have to navigate Alzheimer's disease alone. Whether you are seeking answers about new memory concerns, exploring treatment after a recent diagnosis, or looking for additional care opportunities, Dr. Vandersluis and the Neurology Diagnostics team are dedicated to helping you understand your options and take the next steps with confidence, compassion, and support.